We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
26
DBV Technologies
DBVT
$805M
$77.9M 0.34%
1,461,426
– –
NRIX icon
27
Nurix Therapeutics
NRIX
$2.43B
$76.3M 0.33%
2,454,082
+665,161
+37% +$25.2M
KYMR icon
28
Kymera Therapeutics
KYMR
$8.65B
$76.1M 0.33%
1,959,211
– –
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.34B
$74M 0.32%
3,479,873
+1,165,000
+50% +$33.8M
INSM icon
30
Insmed
INSM
$22.5B
$73.4M 0.32%
2,156,001
– –
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$71.8M 0.31%
1,674,004
+777,453
+87% +$36.8M
NBIX icon
32
Neurocrine Biosciences
NBIX
$18.2B
$65.8M 0.29%
676,975
– –
KRYS icon
33
Krystal Biotech
KRYS
$10.6B
$58.6M 0.25%
760,412
+61,538
+9% +$4.47M
FMTX
34
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$56.7M 0.25%
2,024,876
– –
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$55.1M 0.24%
599,110
– –
BCEL
36
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$54.2M 0.23%
3,532,760
– –
ZYME icon
37
Zymeworks
ZYME
$1.62B
$54M 0.23%
1,708,472
– –
ADAP
38
DELISTED
Adaptimmune Therapeutics
ADAP
$52.2M 0.23%
9,830,877
– –
KNSA icon
39
Kiniksa Pharmaceuticals
KNSA
$6.12B
$51.8M 0.22%
2,799,577
– –
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.5B
$50.6M 0.22%
444,444
– –
NGNE icon
41
Neurogene
NGNE
$648M
$47M 0.2%
191,087
– –
IMTX icon
42
Immatics
IMTX
$1.18B
$44.8M 0.19%
3,992,756
+2,187,731
+121% +$24.8M
DSGN icon
43
Design Therapeutics
DSGN
$741M
$43M 0.19%
+1,436,636
New +$48.5M
ACHL
44
DELISTED
Achilles Therapeutics
ACHL
$42.9M 0.19%
+2,591,366
New +$42.9M
MRUS
45
DELISTED
Merus
MRUS
$42.6M 0.18%
2,037,469
– –
VSTM icon
46
Verastem
VSTM
$517M
$42M 0.18%
1,418,275
+572,938
+68% +$16M
BCAB icon
47
BioAtla
BCAB
$5.48M
$41.9M 0.18%
16,500
– –
ALT icon
48
Altimmune
ALT
$576M
$39M 0.17%
2,758,518
+874,067
+46% +$14.1M
FLGT icon
49
Fulgent Genetics
FLGT
$557M
$38.7M 0.17%
401,016
-94,557
-19% -$9.76M
PTGX icon
50
Protagonist Therapeutics
PTGX
$8.68B
$37.2M 0.16%
1,436,192
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Baker Bros. Advisors held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Baker Bros. Advisors added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Baker Bros. Advisors fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Baker Bros. Advisors opened 11 new positions and closed 12 in Q1 2021.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.